Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apeptico, a biotechnology company, has completed the Phase I clinical trial for its pulmonary sodium ion channel activator AP301, which is used to treat oedematous respiratory failure.
Subscribe to our email newsletter
AP301, an orally inhaled drug candidate is used against respiratory failure caused by pulmonary oedema that activates lung oedema reabsorption.
The Phase I single-center clinical trial assessed the safety, tolerability and pharmacokinetic profile of AP301 in an orally inhaled, double-blind, randomized, placebo-controlled, dose escalation study in 48 healthy male volunteers.
The data demonstrated that the drug was safe and well-tolerated at all doses.